A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Public ClinicalTrials.gov record NCT01894958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome
Study identification
- NCT ID
- NCT01894958
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- NNZ-2566 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 45 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2013
- Primary completion
- Aug 31, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Feb 4, 2018
2014 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 16
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis MIND Institute | Sacramento | California | 95817 | — |
| Children's Hospital Colorado | Denver | Colorado | 80045 | — |
| Children's National Hospital | Washington D.C. | District of Columbia | 20010 | — |
| Emory University | Atlanta | Georgia | 30033 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Kennedy Krieger Institute | Baltimore | Maryland | 21205 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of Nebraska | Omaha | Nebraska | 68588 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Autism & Developmental Medicine Institute Geisinger Health System | Lewisburg | Pennsylvania | 17837 | — |
| Suburban Research Associates | Media | Pennsylvania | 19063 | — |
| Greenwood Genetic Center | Greenwood | South Carolina | 29646 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37235 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01894958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01894958 live on ClinicalTrials.gov.